EFPIA calls on the EU and its member states to secure exemptions for innovative medicines and to develop solutions that bolster investment in pharmaceutical research, development, and production.

EFPIA’s Director General, Nathalie Moll, highlights that tariffs hinder industry resilience, increase barriers to global health innovation, and negatively impact patient access to new treatments.

She also stresses that adding barriers to supply chains hampers national resilience and innovation, further threatening the European pharmaceutical sector's competitiveness.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has strongly criticized the recent EU-US trade agreement for imposing a 15% tariff on innovative medicines, breaking a 30-year commitment to eliminate tariffs on such pharmaceuticals to protect patients.

EFPIA emphasizes that this tariff threatens patient access, the competitiveness of the European pharmaceutical sector, and global research and development efforts, especially without clear exemptions or transparency on future trade and pricing policies.

In Portugal, industry association APIFARMA aligns with EFPIA's stance and will continue monitoring discussions about potential exemptions for innovative medicines.

The federation warns that the tariffs could divert billions of euros from medical research and development, jeopardizing innovation and patient care across Europe.

The tariffs could cost the European pharmaceutical industry approximately 18 billion euros in export costs to the US, which exported 120 billion euros worth of pharmaceuticals from the EU in 2024, a figure significantly higher than exports of other sectors like automobiles.